Logotype for GH Research PLC

GH Research (GHRS) investor relations material

GH Research Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for GH Research PLC
Q3 2025 earnings summary5 Nov, 2025

Executive summary

  • Full Phase 2b clinical trial dataset for GH001 in treatment-resistant depression (TRD) reported, meeting primary endpoint with significant MADRS reduction at Day 8 (p<0.0001).

  • Long-term safety and efficacy data from open-label extension showed 73% remission at 6 months, with no serious adverse events or suicidal behavior.

  • Engagement with FDA on GH001 IND clinical hold ongoing, with only one hold topic remaining.

  • Global pivotal program for GH001 expected to initiate in 2026.

Financial highlights

  • Cash, cash equivalents, and marketable securities totaled $293.9 million as of September 30, 2025, up from $182.6 million at December 31, 2024.

  • Research and development expenses were $10.6 million for Q3 2025, up from $8.4 million in Q3 2024, mainly due to increased technical development and employee expenses.

  • General and administrative expenses were $6.0 million for Q3 2025, up from $4.2 million in Q3 2024, primarily due to higher professional fees and employee expenses.

  • Net loss for Q3 2025 was $14.0 million ($0.23 per share), compared to $12.1 million ($0.23 per share) in Q3 2024.

  • Total comprehensive loss for Q3 2025 was $14.1 million.

Outlook and guidance

  • Ongoing engagement with FDA to resolve the remaining clinical hold topic for GH001 IND.

  • Global pivotal program for GH001 in TRD planned to start in 2026.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next GH Research earnings date

Logotype for GH Research PLC
Q4 202527 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next GH Research earnings date

Logotype for GH Research PLC
Q4 202527 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative therapies for psychiatric and neurological disorders. The company's primary area of research is centered on 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a psychoactive compound, which is being developed for treating treatment-resistant depression (TRD) and other mental health conditions. GH Research's leading product candidate, GH001, is an inhalable form of mebufotenin, currently in Phase 2b clinical trials for TRD, as well as in earlier trials for Bipolar II disorder and postpartum depression. Additionally, the company is developing GH002, an intravenous formulation, and GH003, an intranasal product. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage